Nanocapsules: A novel formulation technology for platinum-based anticancer drugs

Future Lipidology

Volumn 2, Issue 4, 2007, Pages 445-453

  Hamelers, Irene H L ^a   de Kroon, Anton I P M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anticancer drugs; Carboplatin; Cisplatin; Formulation technology; Improved cytotoxicity; Lipid formulation; Nanocapsules; Oxaliplatin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; DAUNORUBICIN; DIOLEOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLSERINE; DIURETIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPTAPLATIN; LIPOPLATIN; LIPOXAL; LOBAPLATIN; MACROGOL; NANOCAPSULE; NEDAPLATIN; OXALIPLATIN; PLATINUM COMPLEX; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; ENCAPSULATION; GASTROINTESTINAL TOXICITY; HEARING LOSS; HEMATOLOGIC DISEASE; HUMAN; HYDRATION; KIDNEY DISEASE; NANOTECHNOLOGY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TINNITUS;

EID: 34547877648     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.2.4.445     Document Type: Review

References (59)

1. Rosenberg B, Vancamp L., Krigas T: Inhibition of cell division in Escherichia coli by eletrolysis products from a platinum electrode. Nature 205, 698-699 (1965).
2. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307-20 (2005).
3. Douple EB: cis-Diamminedichloro-platinum (II): effects of a representative metal coordination complex on mammalian cells. Pharmacol. Ther. 25, 297-326 (1984).
4. Speelmans G, Sips WH, Grisel RJ et al.: The interaction of die anticancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration. Biochim. Biophys. Acta 1283, 60-66 (1996).
5. Speelmans G, Staffhorst RW, Versluis K. Reedijk J, de Kruijff B: Cisplatin complexes with phosphatidylserine in membranes. Biochemistry 36, 10545-10550 (1997).
6. el-Khateeb M, Appleton TG, Gahan LR. Charles BG, Berners-Price SJ, Bolton AM: Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR. techniques. J. Inorg. Biochem. 77, 13-21 (1999).
7. Reedijk J: New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc. Natl Acad Sci. USA 100, 3611-3616 (2003).
8. Akaboshi M, Kawai K, Maki H, Akuta K. Ujeno Y, Miyahara T: The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration. Jpn J. Cancer Res. 83, 522-526 (1992).
9. Fichtinger-Schepman AM, Lohman PH, Berends F, Reedijk J, van Oosterom AT: Interactions of the antitumour drug cisplatin with DNA in vitro and in vivo. IARC Sci. Publ. 83-99 (1986).
10. Dijt, FJ, Fichtinger-Schepman AM, Berends F, Reedijk J: Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-denficient human fibroblasts. Cancer Res. 48, 6059-6062 (1988).
11. Cooley ME, Davis LE, DeStefano M, Abrahm J: Cisplatin: a clinical review. Part I-Current uses of cisplatin and administration guidelines. Cancer Nurs. 17, 173-184 (1994).
12. Fillastre JP, Raguenez-Viotte G: Cisplatin nephrotoxicity. Toxicol. Lett. 46, 163-175 (1989).
13. Ma J, Verweij J, Kolker HJ, van Ingen HE, Stoter G, Schellens JH: Pharmacokinetic-dynamic relationship of cisplatin in vitro: stimulation of an intravenous. bolus and 3 h and 20 h infusion. Br. J. Cancer 69, 852-862 (1994).
14. Schellens JH, Ma J, Planting AS et al.: Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br. J. Cancer 73, 1569-1575 (1996).
15. Wernyj RP, Morin PJ: Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist. Updat. 7, 227-232 (2004).
16. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 (2003).
17. Connors TA, Jones M, Ross WC, Braddock PD, Khokhar AR, Tobe ML: New platinum complexes with anti-tumour activity. Chem. Biol. Interact. 5, 415-424 (1972).
18. Bloemink MJ, Reedijk J: Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Met. Ions Biol. Syst. 32, 641-685 (1996).
19. Harrap KR: Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 12(Suppl. A), 21-33 (1985).
20. van der Vijgh WJ: Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet. 21, 242-261 (1991).
21. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, M Marty: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25, 299-303 (1990).
22. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol. 25, 13-22 (1998).
23. Barnes KR, Lippard SJ: Cisplatin and related anticancer drugs: recent advances and insights. Met. Ions Biol. Syst. 42, 143-177 (2004).
24. Mishima M, Samimi G, Kondo A. Lin X, Howell SB: The cellular pharmacology of oxaliplatin resistance. Eur. J. Cancer 38, 1405-1412 (2002).
25. Cassidy J, Misser JL: Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. 29, 11-20 (2002).
26. Takigawa N, Segawa Y, Ueoka H et al.: Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer. Cancer Chemother. Pharmacol. 46, 272-278 (2000).
27. McKeage MJ, Higgins JD 3rd, Kelland LR: Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991. Br. J. Cancer 64(4), 788-792 (1991).
28. Kim NK, Kim TY, Shin SG et al.: A Phase I study of cis-malonato[(4R, 5R)-4,5-bis (aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies. Cancer 91, 1549-1556 (2001).
29. Gabizon AA, Shmeeda H, Zalipsky S: Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 16, 175-183 (2006).
30. Forssen EA, Male-Brune R, Adler-Moore JP et al.: Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 56, 2066-2075 (1996).
31. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT: Dose dependency of pharmacokinetics and therapeutic efficacy of pegylatedd liposomal doxorubicin (DOXIL) in murine models. J. Drug Target. 10, 539-548 (2002).
32. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19, 424-436 (2001).
33. Hussein M: Pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone as first-line therapy for multiple myeloma. Clin. Lymphoma 4(Suppl. 1), S18-S22 (2003).
34. Leonetti C, Scarsella M, Semple SC et al.: In Vivo administration of liposomal vincristine sensitzes drug-resistant human solid tumors. Int. J. Cancer 110, 767-774 (2004).
35. Koshkina NV, Kleinerman ES, Waidrep C et al.: 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin. Cancer Res. 6, 2876-2880 (2000).
36. Vershraegen CF, Gilbert BE, Huaringa AJ et al.: Feasibility, Phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann. NY Acad. Sci. 922, 352-354 (2000).
37. Colbern GT, Dykes DJ, Engbers C et al.: Encapsulation of the topoisomerase I inhibitor GL147211C in peylated (STEALTH) liposomes. pharmacokinetics and antitumor activity in HT29 colon rumor xenografts. Clin. Cancer Res. 4, 3077-3082 (1998).
38. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA: Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 43, 1-7 (1999).
39. Peleg-Shulman T, Gibson D, Cohen R, Abra R, Barenholz Y: Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim. Biophys. Acta 1510, 278-291 (2001).
40. Miller CR, Bondurant B, McLean SD, McGovern KA, O'Brien DF: Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37, 12875-12883 (1998).
41. Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145-160 (2005).
42. Harrington KJ, Lewanski CR, Northcote AD et al.: Phase I-II study of pegylated liposomal cisplatin (SP1-077) in patients with inoperable head and neck cancer. Ann. Oncol. 12, 493-496 (2001).
43. Meerium Terwogt JM, Groenewegen G, Phum D et al.: Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin, Cancer Chemother. Pharmacol. 49, 201-210 (2002).
44. Vail DM, Kurzman ID, Glawe PC et al.: STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteasarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother. Pharmacol. 50, 131-136 (2002).
45. Zamboni WC, Gervais AC, Egorin MJ et al.: Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother. Pharmacol. 53, 329-336 (2004).
46. Boulikas T: Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol. Rep. 12, 3-12 (2004).
47. Stathopoulos GP, Boulikas T, Vougiouka M et al.: Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study. Oncol. Rep. 13, 589-595 (2005).
48. Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J: Liposomal oxaliplatin in the treatment of advanced cancer. a Phase I study. Anticancer Res. 26, 1489-1493 (2006).
49. Xiao C, Qi X, Maitani Y, Nagai T: Sustained release of cisplatin from multivesicular liposomes: potentiation of antitumor efficacy against S180 murine carcinoma. J. Pharm. Sci. 93, 1718-1724 (2004).
50. Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A: Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 10, 911-920 (1999).
51. Riley CM, Sternson LA: Cisplatin. In: Analytical Profiles of Drug Substances. Florey K (Ed.). Academic Press, NY, USA 78-105 (1985).
52. Burger KN, Staffhorst RW, de Vijlder HC et al.: Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat. Med. 8, 81-84 (2002).
53. Velinova MJ, Staffhorst RW, Mulder WJ et al.: Preparation and stability of lipid-coated nanocapsules of cisplatin: anionic phospholipid specificity. Biochim. Biophys. Acta 1663, 135-142 (2004).
54. Chupin V, de Kroon AI, de Kruijff B: Molecular architecture of nanocapsules, bilayer-enclosed solid particles of cisplatin. J. Am. Chem. Soc. 126, 13816-13821 (2004).
55. Ramachandran S, Quist AP, Kumar S, Lal R: Cisplatin nanoliposomes for cancer therapy: AFM and fluorescence imaging of cisplatin encapsulation, stability, cellular uptake, and toxicity. Langmuir 22, 8156-8162 (2006).
56. Hamelers IH, van Loenen E, Staffhorst RW, de Kruijff B, de Kroon AI: Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin. Mol. Cancer Ther. 5, 2007-2012 (2006).
57. Knox RJ, Friedlos F, Lydall DA, Roberts JJ: Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cisdiamminedichloroplatinum(II) and cisdiammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 46, 1972-1979 (1986).
58. de Kroon AI, Staffhorst RW, de Kruijff B, Burger KN: Cisplatin nanocapsules. Meth. Enzymol. 391, 119-125 (2005).
59. Helleman J, Burger H, Hamelers IH et al.: Impaired cisplatin influx in an A2780 mutant cell line: Evidence for a putative, cis-configuration-specific, platinum influx transporter. Cancer Biol. Ther. 5, 943-949 (2006).